PROGRAM

Start Time	End Time	Paper #		Room
SUNDAY 3 MARCH 2024				
8:00	18:00		Exhibition booth build and exhibitor move-in.	HALL M
15:00	18:00		Speaker Support	Room L2
MONDAY 4 MARCH 2024				
7:30	18:00		Registration Opens	FOYER M
7:30	19:00		Exhibition & Poster Displays Open	HALL M
8:00	17:00		Speaker Support	ROOM L2
9:00	**10:35**		**CONFERENCE OPENING & SESSION 1 : AML**	HALL L
			SPONSORED BY: abbvie	
			CHAIR: A/Prof Dan Thomas and A/Prof Nikki Verrills	
9:00	9:05		Welcome and Conference Opening	
9:05	9:35		**INVITED SPEAKER:** Insights to the Intensive Chemotherapy And Venetoclax in Elderly AML Trial (CAVEAT), Dr Chyn Chua MBBS. FRACP. FRCPA. PhD. Alfred Hospital · Department of Clinical Haematology	
9:35	9:50	42	Proteogenomics coupled with ex vivo profiling to aid therapy selection in AML, Dr Heather Murray, The University of Newcastle and The Hunter Medical Research Institute	
9:50	10:05	34	ERG is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy, Jiarna Zerella, The University of Adelaide	
10:05	10:20	18	Targeting the Leukaemia Stem Cells in Acute Myeloid Leukaemia via Aryl Hydrocarbon Receptor, Dr Alyona Oryshchuk, University of Auckland/Waipapa Taumata Rau	
10:20	10:35	24	Direct, potent and TP53-independent activity of STING agonists against acute myeloid leukaemia, Dr Yin Yuan, WEHI	
10:35	11:05		Morning Tea & Trade Display	HALL M
11:05	**12:25**		**SESSION 2**	HALL L
			CHAIR: Dr Lev Kats and A/Prof Gemma Kelly	
11:05	11:35		**INVITED SPEAKER:** NHMRC funding schemes, including plans for improved equity and diversity, Prof Steve Wesselingh, FRACP FAHMS, Chief Executive Officer, National Health and Medical Research Council	
11:35	12:05		**INVITED SPEAKER:** Towards precision cancer research for Indigenous Australian cancer health equity, Dr Justine Clark, Postdoctoral Research Fellow, Telethon Kids Institute	
12:05	12:25		Session 2 - Questions	
12:25	13:25		Lunch & Trade Display SPONSORED BY: abbvie	HALL M

13:25	**14:55**		**SESSION 3 : AML/MDS**	HALL L
			CHAIR: Dr Andrew Guirguis and Dr Catherine Carmichael	
13:25	13:55		**INVITED SPEAKER:** Understanding AML as an evolutionary process: A clinician's perspective, Dr Carolyn Grove MBBS FRACP FRCPA PhD, Sir Charles Gairdner Hospital and PathWest	
13:55	14:25		**INVITED SPEAKER:** Functional dissection of the cell context-specific contribution of pre-leukemic mutations in human leukemogenesis, Dr Thomas Köhnke, Stanford University	
14:25	14:40	62	C/EBPα Acts as an RNA Binding Protein Essential for, and Promotes End-Stage Macrophage Differentiation, Dr Mahmoud Bassal, Beth Israel Deaconess Medical Center	
14:40	14:55		**Rapid Fire Presentations 1**	
			CHAIR: Dr Chloe Thompson-Peach and Dr Laura Eadie	
		51	Mesenchymal stromal cell senescence is associated with increased risk of progression from MGUS to multiple myeloma, Dr Krzysztof Mrozik, The University of Adelaide	
		65	Cytokine and mutation profiling reveal patterns of innate immune activation in chronic myelomonocytic leukaemia, Dr Monika Kutyna, SAHMRI and CALHN	
		6	Murine mesenchymal stem cells undergo molecular changes after a single passage in culture, Dr Vincent Kuek, Telethon Kids Institute	
		79	Jak2V617F myeloproliferative neoplasm propagating stem cells and pegIFNa treatment alter the bone marrow niche, Dr Jasmin Straube, QIMR Berghofer Medical Research Institute	
		83	Developing novel targeted therapies to prevent relapse in childhood leukaemia, Miss Kunjal Panchal, Telethon Kids Institute	
14:55	15:25		Afternoon Tea & Trade Display	HALL M
15:25	**16:55**		**SESSION 4 : CML**	HALL L
			SPONSORED BY: Takeda	
			CHAIR: Dr Michael Osborn and Prof Deborah White	
15:25	15:55		**INVITED SPEAKER:** Chronic Myeloid Leukaemia: Next Challenges, Prof Tim Hughes, MD, FRACP, FRCPA, FAAHMS, FAA, Precision Cancer Medicine Theme Co-Leader, South Australian Health and Medical Research Institute (SAHMRI) - Clincial Spotlight	
15:55	16:25		**INVITED SPEAKER:** Additional Genetic abnormalities in chronic myeloid leukaemia, Dr Naranie Shanmuganathan MBBS FRACP FRCPA PhD, Consultant Haematologist, Royal Adelaide Hospital & SA Pathology	
16:25	16:40	60	Leukemic transformation STEMming from myeloproliferative neoplasm: clonal evolution and disruption of stem cell heterogeneity, Dr Julian Grabek, Queensland Institute of Medical Research	
16:40	16:55		**Rapid Fire Presentations 2**	
			CHAIR: Dr Donia Moujalled and Dr Teresa Sadras	
		27	Impact of mutant DDX41 variants in innate immunity via STING pathway, Dung An Thanh Nguyen, University of South Australia	
		31	Sensitive measurement of residual disease in granulocytes strongly predicts relapse in chronic myeloid leukaemia patients stopping therapy: dynamics of this biomarker on therapy, Dr Ilaria Stefania Pagani, SAHMRI	
		44	Inhibition of nicotinamide metabolism potentiates venetoclax in AML models, Mawar Karsa, Children's Cancer Institute	
		49	Low heme balances pro-leukemic transcriptional programs with cuproptosis sensitivity, Dr Alexander Lewis, Peter MacCallum Cancer Centre	
		50	Asciminib is effective against ABL1 gene fusions in Acute Lymphoblastic Leukemia but only when the ABL1 SH3 domain is present, Dr Laura Eadie, SAHMRI	
17:00	**19:00**		**Welcome Reception & Poster Session**	HALL M
			POSTER SESSION SPONSORED BY: NOVARTIS	

TUESDAY 5 MARCH 2024

7:00	18:00		Registration Opens	FOYER M
8:00	18:00		Exhibition & Poster Displays Open	HALL M
8:00	17:00		Speaker Support	ROOM L2
7:15	**08:30**		**Breakfast Session - Meet the Experts**	GILBERT SUITE
9:00	**11:05**		**SESSION 5 : CAR-T/NK CELLS**	HALL L
			CHAIR: Prof Timothy Hughes and Prof Maher Gandhi	
9:00	9:40		**INVITED SPEAKER:** Mapping phenotypes and lineage history in human somatic evolution with single-cell multi-omics, Prof Dan Landau, MD, PhD, Associate Professor of Medicine, Division of Hematology and Medical Oncology, Associate Professor of Physiology and Biophysics, Weill Cornell Medicine, Core Member, New York Genome Center (Virtual)	
9:40	10:20		**INVITED SPEAKER:** NK cells: next generation cell therapies for cancer, Prof Katy Rezvani, MD, PhD, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine. The University of Texas MD Anderson Cancer Center (Virtual)	
10:20	10:50		**INVITED SPEAKER:** Update of CAR T cell therapy for the treatment of blood cancers: milestones, obstacles and future directions, Dr Siok Tey, Clinician scientist - Haematology, Bone Marrow Transplantation and Cell Therapy, QIMR Berghofer Medical Research Institute	
10:50	11:05	30	A rare cell state underpins diverse mechanisms of adaptive resistance to CAR T-cell therapy in B-cell acute lymphoblastic leukemia, Dr James Kuzich, Peter MacCallum Cancer Centre	
11:05	11:35		Morning Tea & Trade Display	HALL M
11:35	**12:35**		**SESSION 6 : AML**	HALL L
			CHAIR: Prof David Curtis and Dr Megan Bywater	
11:35	11:50	81	The stoichiometry of the IL-3 receptor controls stemness programs and cell fate in acute myeloid leukaemia, Dr Winnie Kan, Centre for Cancer Biology	
11:50	12:05		Therapy-related myeloid neoplasm: when genetics collide with environment. A/Prof. Devendra Hiwase, MBBS, MD, FRACP, FRCPA, PhD, Royal Adelaide Hospital	
12:05	12:20	57	Pharmacological binding site restriction redirects pioneer transcription factor activity in Acute Myeloid Leukemia, Dr Samuel Taylor, Albert Einstein College Of Medicine (Virtual)	
12:20	12:35	12	Mutant Dnmt3a expands a quiescent progenitor population with myeloid bias in Npm1c-Flt3ITD Acute Myeloid Leukaemia, Dr Paniz Tavakoli, QIMR Berghofer	
12:35	13:35		Lunch & Trade Display SPONSORED BY: THE UNIVERSITY of ADELAIDE	HALL M
13:35	**14:30**		**SESSION 7 : Metcalf Oration**	HALL L
13:35	13:45		Metcalf Introduction by Professor Steven Lane, QIMR Berghofer	
13:45	14:30		Metcalf Oration: Beyond APML: intrinsic and extrinsic roles of retinoic acid receptors in regulating normal and malignant haematopoiesis, Prof Louise Purton, PhD, Laboratory Head, St Vincent's Institute Medical Research	
14:30	15:00		Afternoon Tea & Trade Display	HALL M
15:00	**16:30**		**SESSION 8 : ALL**	HALL L
			CHAIR: A/Prof Rishi Kotecha and Dr Diane Hanna	
15:00	15:30		**INVITED SPEAKER:** Progress in AYA ALL - the Australasian and Leukaemia Group ALL06 and ALL09 Trials, A/Prof. Matthew Greenwood BMed (Hons) FRACP FRCPA. Senior Staff Specialist in the Department of Haematology and Transfusion Medicine and Director, BMT and Cellular Therapy Program, Royal North Shore Hospital - Clinical Spotlight	
15:30	16:00		**INVITED SPEAKER:** Exploiting Molecular Vulnerabilities in T-cell acute lymphoblastic leukaemia, Dr Charles De Bock, Team Leader, Functional Genomics of Leukemia, Children's Cancer Institute	
16:00	16:15	20	FLT3 signalling promotes tumour expansion, chemotherapy-resistance and regeneration in Early T-cell Precursor Acute Lymphoblastic Leukemia, Dr Cedric Tremblay, University of Manitoba	
16:15	16:30	15	Investigating the role of chemokine-like factor in paediatric B-ALL relapse, Caleb Lill, The University of Adelaide	

16:30	**17:45**		**SESSION 9 : CLL & LYMPHOMA**	HALL L
			SPONSORED BY: AstraZeneca	
			CHAIR: Prof Andrew Roberts and Prof Richard D'Andrea	
16:30	17:00		**INVITED SPEAKER:** The Lymphoma microenvironment: a complex and complicated neighbourhood, Prof Maher Gandhi MBChB, FRCP, FRCPath, FRACP, PhD. Executive Director of Mater Research; Director Mater Research Institute-UQ; Haematologist (Princess Alexandra and Mater Hospitals)	
17:00	17:15	74	Informing therapeutic approaches for p53 defective cancers, A/Prof Gemma Kelly, WEHI	
17:15	17:30	66	Boosting apoptosis of TP53-mutant blood cancers using combined BH3-mimetic drug and STING agonist therapy, Dr Sarah Diepstraten, WEHI	
17:30	17:45	2	Exploiting cancer cell addiction to cyclin-dependent-kinase 11 (CDK11) dependent transcription cycles for cancer therapy., Dr Jennifer Devlin, Peter MacCallum Cancer Centre	
17:45	19:15		Break	
19:15	**Late**		**Social Dinner** **Ian McLachlan Room, Adelaide Oval (Enter via Southern Gates)**	

WEDNESDAY 6 MARCH 2024

8:00	15:30		Registration Opens	FOYER M
8:00	15:30		Exhibition & Poster Displays Open	HALL M
8:00	14:00		Speaker Support	ROOM L2
9:00	**10:40**		**SESSION 10 : MPN / Stem Cells & Microenvironment**	HALL L
			CHAIR: Prof Stefan Bohlander and Prof Louise Purton	
9:00	9:40		**INVITED SPEAKER:** Myeloproliferative neoplasms – JAK/STAT signalling and stem cell subversion, Prof Tony Green, PhD, FRCP, FRCPath, FMedSci, Professor of Hemato-oncology, Wellcome-MRC Cambridge Stem Cell Institute and Department of Haematology, University of Cambridge	
9:40	10:10		**INVITED SPEAKER:** Modelling treatment response and disease progression in Jak2-mutant myeloproliferative neoplasms, Dr Megan Bywater PhD Senior Research Officer, QIMR Berghofer Medical Research Institute	
10:10	10:25	59	Determining the impact of venetoclax and azacytidine treatment on the bone marrow niche, Dr Steven Ngo, Francis Crick Institute	
10:25	10:40	76	Aspirin modifies the adverse effects of clonal hematopoiesis in the healthy elderly, Professor David Curtis, Monash University	
10:40	11:10		Morning Tea & Trade Display	HALL M
11:10	**12:40**		**SESSION 11 : SYSTEMS BIOLOGY**	HALL L
			CHAIR: A/Prof Antiopi Varelias and Dr Omer Gilan	
11:10	11:40		**INVITED SPEAKER:** The role of the microbiota in responses to and recovery from cancer therapy, Prof David Lynn BA, MSc, PhD. Director, Computational & Systems Biology Program, South Australian Health & Medical Research Institute (SAHMRI) - Scientific Spotlight	
11:40	12:10		**INVITED SPEAKER:** Gene Regulatory Network Dynamics in Acute Myeloid Leukemia: AP-1 and RUNX1 at the centre, Prof Constanze Bonifer, Chair of Experimental Haematology, Founding Director of the Birmingham Centre of Genome Biology, Institute for Cancer and Genomic Sciences, University of Birmingham	
12:10	12:25	36	Antibiotic induced gut dysbiosis exacerbates acute lymphoblastic leukaemia progression and decreases response to targeted therapy in vivo, Dr Elyse Page, SAHMRI	
12:25	12:40	26	Synergy of Stag2-cohesin loss results in expansion of Npm1c-mutant hematopoietic stem and progenitor cells, Dr Jane Xu, Columbia Irving Medical Centre	
12:40	13:40		Lunch & Trade Display	HALL M
13:40	**15:25**		**SESSION 12 : MULTIPLE MYELOMA**	HALL L
			CHAIR: A/Prof David Yeung and Dr Angie Yong	
13:40	14:10		**INVITED SPEAKER:** Meeting in the Middle- Basic Science Translated to Clinical Successes, A/Prof Cindy Lee, Royal Adelaide Hospital	
14:10	14:25	37	A functional genomic screen to identify novel genes involved in multiple myeloma tumour development, Hayley Parkinson, The University of Adelaide	
14:25	14:40	23	Targeted Inhibition of Myeloperoxidase (MPO): A new Therapeutic Strategy for the Treatment of Multiple Myeloma, Connor Williams, The University of Adelaide	
14:40	14:55	55	Menin controls enhancer function and essential cell identity circuits in multiple myeloma, Dr Emily Gruber, Peter MacCallum Cancer Centre	
14:55	15:25		Conference Closing & Awards Presentation	
15:25			Close	

POSTER DISPLAYS

Posters will be displayed from Monday 4 March to Wednesday 6 March in Hall M.
All poster presenters are encouraged to be alongside their poster during the allocated poster session and during schedule breaktimes where possible.

Paper #	Poster #	Theme	
3	P1	Acute Lymphoblastic Leukaemia	Judicious use of precise FISH panels guided by population prevalence may assist pragmatic diagnosis of Ph-like ALL - A Systematic Review, Dr Jane Thompson, SAHMRI
4	P2	Acute Lymphoblastic Leukaemia	Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5::JAK2 Fusion In Vitro: Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia, Dr Jane Thompson, SAHMRI
5	P3	Acute Lymphoblastic Leukaemia	Transcriptomic Profiling Identifies Changes in the Cell Cycle with Early to Late-Stage Disease Transition in B-Cell Acute Lymphoblastic Leukaemia, Dr Vincent Kuek, Telethon Kids Institute
7	P4	Acute Lymphoblastic Leukaemia	Enhancing Precision and Eliminating Reference Bias: Building a B-cell Acute Lymphoblastic Leukaemia Specific Pan-Genome Graph for Improved Genomic Alignment, Miss Ashlee Thomson, SAHMRI
14	P5	Acute Lymphoblastic Leukaemia	Microbiome dysbiosis promotes early splenic engraftment in a specific-pathogen-free murine model of pre-B-ALL, Ms Cate Cheney, SAHMRI
17	P6	Acute Lymphoblastic Leukaemia	Efficacy of asciminib against ABL2 fusion genes in the treatment of high-risk Ph-like Acute Lymphoblastic Leukaemia, Mr Elias Lagonik, SAHMRI, The University of Adelaide
21	P7	Acute Lymphoblastic Leukaemia	ScanDALL: Targeted prediction of intragenic deletions from mRNA-seq data, Miss Jacqueline Rehn, SAHMRI
29	P8	Acute Lymphoblastic Leukaemia	Playing molecular catch: extracellular vesicle-mediated receptor expression and potential "second hit" leukaemic transformation in a primed model of B-cell Acute Lymphoblastic Leukaemia, Mr Maxim Buckley, The University of Adelaide and SAHMRI
32	P9	Acute Lymphoblastic Leukaemia	Pivekimab sunirine (PVEK), a CD123 antibody-drug conjugate, exerts profound activity in preclinical models of paediatric acute lymphoblastic leukaemia, Ben Watts, Children's Cancer Institute
33	P10	Acute Lymphoblastic Leukaemia	CRISPR-directed chromosomal translocations provide novel insights into leukaemia initiation, Fatimah Jalud, Peter MacCallum Cancer Centre
40	P11	Acute Lymphoblastic Leukaemia	Adolescent/Young Adult B-ALL patients enrolled in the Australasian Leukaemia & Lymphoma Group ALL09 "SUBLIME" study with a complete MRD response to blinatumomab have increased cytotoxic central memory T-cells, Dr Susan Heatley, SAHMRI
78	P12	Acute Lymphoblastic Leukaemia	Characterising NTRK1 overexpression in ETV6::RUNX1 positive acute lymphoblastic leukaemia, Mr Luke Quinlan, SAHMRI
50	P13	Acute Lymphoblastic Leukaemia	Asciminib is effective against ABL1 gene fusions in Acute Lymphoblastic Leukemia but only when the ABL1 SH3 domain is present, Dr Laura Eadie, SAHMRI
83	P14	Acute Lymphoblastic Leukaemia	Developing novel targeted therapies to prevent relapse in childhood leukaemia, Miss Kunjal Panchal, Telethon Kids Institute
27	P15	Acute Myeloid Leukaemia	Impact of mutant DDX41 variants in innate immunity via STING pathway, Dung An Thanh Nguyen, University of South Australia

44	**P16**	Acute Myeloid Leukaemia	Inhibition of nicotinamide metabolism potentiates venetoclax in AML models, Mawar Karsa, Children's Cancer Institute
13	**P17**	Acute Myeloid Leukaemia	Development of a precision medicine platform for paediatric acute myeloid leukaemia, Dr Patrick Connerty, Children's Cancer Institute
19	**P18**	Acute Myeloid Leukaemia	A PICALM/MLLT10 Zebrafish Leukemia Model Which is Serially Transplantable, Dr Omid Delfi, University of Auckland
28	**P19**	Acute Myeloid Leukaemia	Targeting MLL-CBP fusion with CBP inhibitors as a treatment for leukemia, Cristina Oliveira-Mateos, Peter MacCallum Cancer Centre
39	**P20**	Acute Myeloid Leukaemia	Examining the role of EMT factor, SNAI1, in Acute Erythroid Leukemia (AEL) pathogenesis, Dr. Catherine Carmichael, Hudson Institute of Medical Research
63	**P21**	Acute Myeloid Leukaemia	Regulation of IL-3 receptor expression on leukemic stem cells and multi-potent progenitors by anti-inflammatory cytokines: new opportunities for targeting CD123+ acute myeloid leukaemia, Miss Sepideh Azizi, Ccb, Adelaide University
68	**P22**	Acute Myeloid Leukaemia	Relapse in acute myeloid leukaemia following BH3-mimetic treatment: role of BAK (and BAX), Dr Karla C. Fischer, WEHI
72	**P23**	Acute Myeloid Leukaemia	Translating Clinical Discoveries into Models for Understanding Disease Progression in Hereditary Haematological Malignancies: From Pre-Leukemic States to MDS/AML, Dr Claire Homan, Centre for Cancer Biology
77	**P24**	Acute Myeloid Leukaemia	Examining the efficacy of targeting mutant TET2 in AML, Leeann Desouza, Centre For Cancer Biology, University of South Australia and SA Pathology
82	**P25**	Acute Myeloid Leukaemia	Preclinical evaluation of bisantrene alone and in combination with decitabine for Acute Myeloid Leukemia, A/prof Nikki Verrills, University of Newcastle
47	**P26**	Cell Therapy	Hypoxia impairs hypomethylating agent efficacy and alters downstream transcriptional responses in Acute Myeloid Leukaemia, Mr Sam Humphries, Hunter Medical Research Institute
54	**P27**	Epigenetics	Irreversible polycomb-mediated gene repression is essential for Menin inhibitor efficacy in leukaemia, Dr Omer Gilan, Monash University
58	**P28**	Epigenetics	Investigating the molecular basis of mRNA stability in leukemia, Dr Mary-Jane Tsang, Peter MacCallum Cancer Centre
61	**P29**	Epigenetics	Genome-Wide Methylation Sensitive Elements Demarcate Targetable Regulatory Elements for Controllable Gene Activation, Dr Mahmoud Bassal, Beth Israel Deaconess Medical Center
69	**P30**	Epigenetics	Engineering a human model of TET2-mutated pre-leukemic monocyte/macrophage to understand the biology of chronic myelomonocytic leukemia, Maha Kamel, The University of Adelaide
56	**P31**	Genomics	CRISPR activation screens identify co-drivers of DNMT3a mutant haematopoietic malignancies, Ms Amali Cooray, WEHI
73	**P32**	Genomics	Navigating The Duality of Demand-Adapted Haematopoiesis – Malignancy Development and Spontaneous Resolution, Dr Parvathy Venugopal, Centre for Cancer Biology
52	**P33**	Lymphoma	WITHDRAWN: DDX3Y is a synthetic lethal therapeutic target in DDX3X mutated high grade lymphoma, Dr Sam Greenall, Monash University
49	**P34**	Metabolism	Low heme balances pro-leukemic transcriptional programs with cuproptosis sensitivity, Dr Alexander Lewis, Peter MacCallum Cancer Centre
64	**P35**	Myelodysplasic Syndrome	High prevalence of IDH mutation in myeloid neoplasm with concomitant autoimmune rheumatic disorders, Dr Devendra Hiwase, SAHMRI and CALHN

75	**P36**	Myelodysplasic Syndrome	Functional characterisation of the transcriptional effect of all possible missense variants in GATA2 using Multiplex Assays of Variant Effect (MAVE), Mr Wen Teng, The University of Adelaide
67	**P37**	Myelodysplasic Syndrome	Comparison of World Health Organization and International Consensus classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations using an Independent International Cohort, A/Prof Devendra Hiwase, SAHMRI and CALHN
11	**P38**	Myeloma	The development of a pre-clinical model of bortezomib-induced peripheral neuropathy, Ms. Sadia Munir, The University of Adelaide
35	**P39**	Myeloma	Towards a lenalidomide-sensitive C57BL/KaLwRij murine model of multiple myeloma, Ms Emma Cheney, The University of Adelaide
71	**P40**	Myeloma	Desmoglein-2 expression by multiple myeloma is an independent predictor of poor prognosis that can be rapidly identified by flow cytometry, Dr Barb McClure, Center for Cancer Biology (UniSA & SA Pathology)
51	**P41**	Myeloma	Mesenchymal stromal cell senescence is associated with increased risk of progression from MGUS to multiple myeloma, Dr Krzysztof Mrozik, The University of Adelaide
9	**P42**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	TIM-3 expression on T-cells is a predictor of treatment free remission in chronic myeloid leukaemia, Mrs Jade Clarson, SAHMRI
10	**P43**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Targeting Oxidative Phosphorylation and Glutaminolysis to Overcome Resistance to Tyrosine Kinase Inhibitors in CML, Jane James, SAHMRI
16	**P44**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Unpacking the role of lipid storage in treatment resistant chronic myeloid leukaemia cells, Miss Molly Tolland, SAHMRI
25	**P45**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Acquisition of mutations in key cancer genes is associated with acquired imatinib resistance in blast phase chronic myeloid leukaemia cell lines, Miss Adelina Fernandes, University of Adelaide
41	**P46**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	OXPHOS remodeling in chronic myeloid leukaemia involves mtDNA mutations and is associated with better response to imatinib, Dr Ilaria Stefania Pagani, SAHMRI
53	**P47**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Neoepitope Targeting with a Monoclonal Antibody to Improve Outcomes in Myelofibrosis, Dr Chloe Thompson-Peach, The University of Adelaide
65	**P48**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Cytokine and mutation profiling reveal patterns of innate immune activation in chronic myelomonocytic leukaemia, Dr Monika Kutyna, SAHMRI and CALHN
31	**P49**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Sensitive measurement of residual disease in granulocytes strongly predicts relapse in chronic myeloid leukaemia patients stopping therapy: dynamics of this biomarker on therapy, Dr Ilaria Stefania Pagani, SAHMRI
79	**P50**	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Jak2V617F myeloproliferative neoplasm propagating stem cells and pegIFNa treatment alter the bone marrow niche, Dr Jasmin Straube, QIMR Berghofer Medical Research Institute
38	**P51**	New Therapeutic Approaches	Targeting epigenetic mechanisms and metabolic reprogramming in acute myeloid leukaemia, Dr Danielle Bond, The University of Newcastle
48	**P52**	New Therapeutic Approaches	Polyamine depletion limits progression of acute leukaemias, Mawar Karsa, Children's Cancer Institute
70	**P53**	New Therapeutic Approaches	Suppression of KRAS and CBL mutations and hematological improvement by Lenzilumab and Azacitidine treatment in proliferative chronic myelomonocytic leukemia, Maha Kamel, The University of Adelaide
22	**P54**	Stem Cells and Microenvironment	Co-culture System Reveals Stromal-Mediated Anthracycline Resistance in Chronic Myeloid Leukaemia, Miss Rhiannon Panting, Telethon Kids Institute
6	**P55**	Stem Cells and Microenvironment	Murine mesenchymal stem cells undergo molecular changes after a single passage in culture, Dr Vincent Kuek, Telethon Kids Institute